Sana Biotechnology Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2018 - 2019
Net Income	-266.76	-283.26	-269.48	-355.93	-285.31	Upgrade
Depreciation & Amortization	15.5	17.54	15.63	11.07	5.92	Upgrade
Asset Writedown & Restructuring Costs	1.89	7.01	-	-	-	Upgrade
Stock-Based Compensation	37.68	35.53	38.34	22.36	5.83	Upgrade
Other Operating Activities	-10.28	-49.03	-82.08	61.64	129.42	Upgrade
Change in Accounts Payable	1.38	1.03	1.06	-0.27	1.98	Upgrade
Change in Other Net Operating Assets	-2.56	17.58	6.48	10.07	4.17	Upgrade
Operating Cash Flow	-223.15	-253.58	-290.05	-251.05	-137.98	Upgrade
Capital Expenditures	-33.43	-20.03	-20.88	-29.86	-23.87	Upgrade
Investment in Securities	50.88	192.04	231.44	-211.36	-228.69	Upgrade
Other Investing Activities	-	-	-	-4.57	-	Upgrade
Investing Cash Flow	17.45	172.01	210.56	-245.8	-252.56	Upgrade
Long-Term Debt Issued	7.74	-	-	-	-	Upgrade
Net Debt Issued (Repaid)	7.74	-	-	-	-	Upgrade
Issuance of Common Stock	192.01	31.65	4.91	631.75	0.15	Upgrade
Financing Cash Flow	199.75	31.65	4.91	631.75	435.69	Upgrade
Net Cash Flow	-5.95	-49.92	-74.58	134.9	45.14	Upgrade
Free Cash Flow	-256.58	-273.61	-310.93	-280.92	-161.85	Upgrade
Free Cash Flow Per Share	-1.11	-1.41	-1.65	-1.69	-12.44	Upgrade
Levered Free Cash Flow	-168.6	-206.93	-140.89	-138.16	-166.01	Upgrade
Unlevered Free Cash Flow	-168.6	-206.93	-140.89	-138.16	-166.01	Upgrade
Change in Net Working Capital	18.68	35.67	4.33	-61.44	-8.84	Upgrade

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q